Lilly/BI biosimilar Lantus approved in Europe
This article was originally published in Scrip
Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.
You may also be interested in...
Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.